Melissa Wisdom Named Managing Director of Juul Labs in UK.

Nov.13.2024
Melissa Wisdom Named Managing Director of Juul Labs in UK.
Juul Labs appoints Melissa Wisdom as Managing Director for UK operations, aims to reduce tobacco harm with innovative products.

In recent days, Juul Labs announced on its official website that Melissa Wisdom will be taking on the role of Managing Director, responsible for overseeing Juul Labs' current and future business operations in the United Kingdom.

Melissa Wisdom Named Managing Director of Juul Labs in UK.
Melissa Wisdom | Image source: LinkedIn


It is reported that Melissa previously served as the Chief Commercial Officer at Stonegate Group, where she was responsible for sales, market expansion, and overall business functions. She also held the position of Commercial Director at Diageo, a leading beverage company, and has held senior positions at various well-known domestic and international brands.


Melissa stated, "Becoming the Director General of Juul Labs is an exciting opportunity for me to contribute to the company's bold vision for the future - achieving long-term success through responsible innovation and investment in high-quality, scientifically supported products.


Juul Labs CEO KC Crosthwaite said, "With the introduction of new legislation in the UK and evolving regulatory environments in multiple markets, Melissa's leadership will play a crucial role in our efforts to reduce the harms of tobacco, particularly by providing high-quality product technology to adult smokers to help them stay away from traditional tobacco.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G said it plans to cancel all treasury shares it holds, totaling 10,866,189 shares, representing about 9.5% of shares outstanding, in line with Korea’s third amendment to the Commercial Act requiring companies to cancel repurchased shares within one year. The company also disclosed progress on its shareholder-return plan and multiple agenda items for next month’s shareholders meeting.
Feb.26
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar’s Ministry of Health said it has received cabinet authorization to enforce an e-cigarette ban under the Essential Supplies and Services Law, listing prohibited acts including the import, export, sale, possession, storage, carrying, distribution and use of vaping products.
Feb.26 by 2FIRSTS.ai
MEPs seek Commission answers over EU trade officials’ contacts with PMI
MEPs seek Commission answers over EU trade officials’ contacts with PMI
POLITICO reports that five members of the European Parliament’s health committee want to invite the European Commission to answer questions about its contacts with Philip Morris International (PMI), following a POLITICO and The Examination investigation into extensive meetings between EU trade officials and tobacco lobbyists.
Jan.15 by 2FIRSTS.ai
BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
BAT says a U.S. import block on some disposable vapes could cut illegal sales by about a third
Reuters reported that British American Tobacco (BAT) CEO Tadeu Marroco said a potential U.S. move to block imports of some disposable vapes could reduce the market for unregulated e-cigarettes by as much as a third, though any impact is unlikely before 2027.
Feb.13 by 2FIRSTS.ai
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai